EU regulators will decide this week decide whether several new treatments – including Roche’s hemophilia drug, Hemlibra (emicizumab), which is being fast-tracked through the system – should be recommended for marketing authorization.
Hemlibra is among the eight initial marketing authorizations that the European Medicines Agency’s key advisory panel, the Committee for Medicinal...








